Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs United Parcel Service Inc (UPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs United Parcel Service Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $282.7 (market cap $39.89B), while United Parcel Service Inc trades at $113.5 (market cap $95.60B). The key difference: United Parcel Service Inc is far larger — about 2.4× Alnylam Pharmaceuticals, Inc.'s market cap, and United Parcel Service Inc pays a 5.83% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | UPS | |
|---|---|---|
Market Cap | $39.89B | $95.60B |
Sector | Health | Industrials |
52-Week High | $491.22 | $120.00 |
52-Week Low | $278.09 | $82.58 |
Enterprise Value | $38.15B | $118.46B |
Volume | — | 2,288,643 |
Dividend Yield | — | 5.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
UPS trades at $112.47, up 1.56% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 33.41% ROE and 5.94% net margin, though revenue has declined from $100.3B in 2022 to $88.66B in 2025. Recent news highlights a $48M investment in healthcare logistics and competition concerns from Amazon's logistics expansion.
Outlook is mixed: valuation appears reasonable with a P/E of 18.2, and analysts give a $112 consensus target, but revenue pressure and competitive threats pose risks. The dividend remains supported by solid cash flow, but growth depends on successful execution in a challenging environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
